Skip to main content
Premium Trial:

Request an Annual Quote

X Prize Foundation Fleshes Out Genomics Competition


In recent months, the genomics community has heard rumblings that the X Prize Foundation will soon announce a cash prize for rapid, cheap whole-genome sequencing. According to a foundation spokesperson, however, the earliest the competition will be announced is this summer. The foundation is in the “prize discovery phase.”

“There are a lot of different things that go into this initial phase, which is determining the roadmap for funding, coming up with a proper, nonconvoluted set of rules,” says Ian Murphy, an X Prize Foundation spokesperson.

The nonprofit X Prize Foundation uses huge cash awards to encourage innovation in scientific fields. It awarded its first prize, for $10 million, in 2004 to Mojave Aerospace Ventures led by Burt Rutan for flying a specially designed aircraft to the sub-orbital altitude of 100 kilometers on two consecutive flights, within two weeks. The foundation is now branching out; projects for space, automobiles, and genomics are in the works.

While Craig Venter, who joined the X Prize Foundation board of trustees last year, initially brought the idea for a genomics prize to the board, Larry Kedes is heading up the advisory committee for the genome prize. Kedes, director of the Institute for Genetic Medicine at the University of Southern California, says the competition structure has yet to be defined.

One possible goal is to award the as-yet-undetermined cash prize to the first team to decode the DNA of 100 or more people in a matter of weeks. The committee will consider a number of other ideas, and, most likely, the competition will avoid specifying a dollar amount in its goal, such as sequencing a genome for $1,000. “We don’t want to have to call accountants in to prove the winner met that,” Kedes says.

— Kate O’Rourke


US Patent 6,998,251. Nanoporous membrane reactor for miniaturized reactions and enhanced reaction kinetics. Inventors: Andras Guttman, Zsolt Ronai, Csaba Barta. Assignee: Syngenta Participations. Issued: February 14, 2006.

The patent describes a method of contacting a first component and a second component with one of a nanoporous membrane comprising pores and a nanoporous bead comprising pores, wherein the first and second components are contacted within the pores, and producing a product from a reaction of the first component with the second component.

US patent application 20060024711. Methods for nucleic acid amplification and sequence determination. Inventors: Stanley Lapidus, Philip Buzby. Filed: February 2, 2006.

The invention provides methods for sequencing a nucleic acid by conducting rolling circle amplification on a circular nucleic acid template, wherein the resulting amplicon is optionally anchored to a substrate in an individually optically resolvable manner, and performing a sequencing reaction.



$20 million

The National Heart, Lung, and Blood Institute will award $20 million over three years for research projects focused on identifying genetic variants related to heart, lung, and blood disorders, and their risk factors through genome-wide association studies. The institute expects to fund four to six projects.


A multi-center team has deposited the draft genome sequence of the rhesus macaque monkey into free public databases for use by the worldwide research community. The Macaca mulatta is the second non-human primate, after the chimpanzee Pan troglodytes, to have its genome sequenced, and is the first of the Old World monkeys to have its DNA deciphered.

Led by scientists at The Institute for Genomic Research and Ohio State University, a team of researchers reported the complete genomes of three emerging pathogens that cause ehrlichiosis: Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Neorickettsia sennetsu.

The J. Craig Venter Institute is conducting resequencing and genotyping research with the University of Washington and Johns Hopkins University on five projects selected by NIH’s National Heart, Lung, and Blood Institute.

There’s no shortage of Solexa news lately. The company, which has said it expects to recognize revenue from its instrument in the first half of this year and to be able to sequence a mammalian genome for $100,000 or less sometime in 2006, has gotten the attention of investment bankers. Analysts at Pacific Growth Equities initiated coverage with a ‘buy’ rating, while those at Leerink Swann & Company gave the stock an ‘outperform’ rating. Meanwhile, Nasdaq moved the sequencing firm’s exchange listing from the Capital Market to the National Market.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.